May ; Journal of Clinical Oncology.
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia
[object Object]. [object Object]. Bogdan Dumitriu . University of Texas MD Anderson Cancer Center. Department. Kelly O'Brien, PhD1*, Adrianna Vlachos2, Stacie M. Anderson1*, Crystiana 1 Department of Pediatric Hematology/Oncology, Erasmus Medical Center BS*, Danielle M.
Aplastic Anemia USA
Townsley, MD, Bogdan Dumitriu, MD, Marie Desierto. MD Anderson Cancer Center Logo Sanjay Mohan, Xingmin Feng, Keyvan Keyvanfar, Neil Dunavin, Danielle M. Townsley, Bogdan Dumitriu, Minoo Battiwalla.
In cohort 1, eltrombopag was initiated after ATG, owing to concern about overlapping hepatotoxic effects, especially when it is coadministered with ATG and cyclosporine.
The average time to transfusion independence was approximately 1 month, and clinically meaningful increments in the neutrophil level occurred within a few weeks after therapy began, even in patients with very severe neutropenia.
The primary outcome was complete hematologic response at 6 months. SSC denotes side scatter. Representative flow-cytometric analyses at these three time points are shown for Patient 67; the numbers in the boxes represent the percentages of cells within the indicated fraction. All times are GMT Reticulocyte count — per cubic millimeter.
Video: Bogdan dimitriu m&d anderson cancer clinic Medical and financial clearance at MD Anderson Cancer Center
Anderson Cancer C. Translational Lung Research Center Heidelberg (TLRC-H), German Dumitriu, Bogdan. This study is being conducted at the Mayo Clinic, Rochester MN Contact: This study is being conducted at University of Texas MD Anderson Cancer Center, Houston, Tx Or Bogdan Dumitriu, M.D., () dumitriub@ gov. University of Texas MD Anderson Cancer Center; Department of Biostatistics. External person. 1 shared. Dumitriu, Bogdan.
National Institutes of Health.
National Center for Biotechnology InformationU. Mott Children's Hospital Dr. Three of the five patients who had a loss of chromosome 7 did not have somatic mutations that were detectable in candidate genes that are recurrently mutated in the myelodysplastic syndrome and acute myeloid leukemia; in the other two patients, small clones that had mutated in ASXL1 or DNMT3A were present but of uncertain significance — findings that were consistent with our earlier report regarding the loss of chromosome 7 after aplastic anemia.
In cohort 1, eltrombopag was initiated after ATG, owing to concern about overlapping hepatotoxic effects, especially when it is coadministered with ATG and cyclosporine. A likely limit to the efficacy of immunosuppression is the stem-cell deficit.
Comparison of Cohorts and Predictors of Response The response rates among the cohorts were compared and were highest in cohort 3, which had the earliest initiation of eltrombopag and the longest duration of treatment Table 2.